FDA's Q4 2026 Docket: Seven Decisions to Watch Across Hepatology, Nephrology and Endocrinology

What Happened

The U.S. Food and Drug Administration heads into the final quarter of 2026 with an unusually concentrated slate of regulatory decisions spanning hepatology, nephrology, cardiovascular disease, endocrinology and dermatology. Industry previews of the fourth-quarter calendar count seven anticipated rulings, several of which could deliver first-in-class approvals.

The earliest marquee decision arrives October 26, the target action date for bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B developed by GSK in partnership with Ionis Pharmaceuticals. The FDA granted the candidate both Priority Review and Breakthrough Therapy designation. If approved, it would become the first therapy to deliver clinically meaningful functional cure rates in chronic hepatitis B — functional cure being defined as undetectable hepatitis B surface antigen sustained for at least 24 weeks after stopping all treatment.

November is expected to bring a cluster of further rulings, including decisions on obinutuzumab for primary membranous nephropathy and bezuclastinib, Cogent Biosciences' oral kinase inhibitor for systemic mastocystosis. The endocrinology docket extends into December, with a December 18 target action date for Camurus' resubmitted acromegaly application.

Who Is Affected

• Chronic hepatitis B patients — a population that today depends on lifelong suppressive therapy; a functional-cure option would be the first of its kind.
• Nephrology and dermatology communities — primary membranous nephropathy and systemic mastocystosis both lack broadly satisfactory targeted options.
• Acromegaly patients — a rare-disease decision that rounds out the year.
• Clinical researchers — each ruling sets regulatory precedent for a novel mechanism class, from antisense oligonucleotides to targeted kinase inhibition.

Timeline

• October 26, 2026 — target action date for bepirovirsen in chronic hepatitis B
• November 2026 — expected decisions on obinutuzumab (primary membranous nephropathy) and bezuclastinib (systemic mastocystosis)
• December 18, 2026 — target action date for Camurus' CAM2029 in acromegaly
• Year-end 2026 — remaining rulings across cardiovascular and dermatology indications

What This Means for Researchers

The bepirovirsen decision is the one to watch for anyone tracking nucleic-acid therapeutics. Antisense oligonucleotides have spent decades confined largely to rare genetic disease; a first-in-class functional-cure approval in hepatitis B would validate the platform for a mass-market indication and could pull investment across the broader oligonucleotide and peptide-therapeutic space.

For the research-chemical community, the quarter also carries a caution. The same agency that green-lights these novel therapies has been sharpening enforcement against unapproved peptide sales, and its fourth-quarter docket is a reminder that the distance between an approved, regulated product and an unregulated research compound remains the central legal and safety fault line in this field.

How to Verify Your Peptides

Whatever the FDA decides this quarter, the burden of verifying what is in a vial stays with the buyer. Any peptide or reagent sourced outside licensed channels should be treated as unverified until tested:

• How third-party lab testing works
• HPLC versus LC-MS: what each method reveals
• Identity, purity and fill-weight reports explained

Safe Alternatives

Researchers do not need to accept supply-chain risk to work with peptides:

• Explore the research-grade peptide landscape
• Compare sources in the vendor directory

Sources

Regulatory announcements; FDA approval records; industry reports.